Antisense interleukin-5 reduces eosinophil infiltration and hyperresponsiveness in an allergic asthma model

Asian Pacific Journal of Allergy and Immunology

Volumn 27, Issue 1, 2009, Pages 35-41

  Huang, Feng Ying ^a   Wang, Cai Chun ^a   Zhou, Song Lin ^a   Huang, Yong Hao ^a   Wang, Hua ^a   Chen, Fan ^a   Lin, Ying Ying ^a   Tan, Guang Hong ^a   Liu, Jun Bao ^a  

^a HAINAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; INTERLEUKIN 5; MESSENGER RNA; OVALBUMIN; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD ANALYSIS; BRONCHUS HYPERREACTIVITY; CELL ACTIVATION; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; EOSINOPHIL; EOSINOPHIL COUNT; GENE TRANSFER; INFLAMMATORY CELL; INHIBITION KINETICS; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; ASTHMA; CELL MOVEMENT; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; EOSINOPHILS; HUMANS; INTERLEUKIN-5; MALE; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; TRANSDUCTION, GENETIC;

EID: 67749084687     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Sugita M, Kuribayashi K, Nakagomi T, Miyata S, Matsuyama T, Kitada O. Allergic bronchial asthma: airway inflammation and hyperresponsiveness. Intern Med 2003; 42: 636-43.
2. Woodruff PG, Khashayar R, Lazarus SC, et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 2001; 108: 753-8.
3. Barthel SR, Johansson MW, McNamee DM, Mosher DF. Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J Leukoc Biol 2008; 83: 1-12.
4. Humbles AA, Lloyd CM, McMillan SJ, et al. A critical role for eosinophils in allergic airways remodeling. Science 2004; 305: 1776-9.
5. Fixman ED, Stewart A, Martin JG. Basic mechanisms of development of airway structural changes in asthma. Eur Respir J 2007; 29: 379-89.
6. Walter MJ, Holtzman MJ. A centennial history of research on asthma pathogenesis. Am J Respir Cell Mol Biol 2005; 32: 483-9.
7. Busse WW, Lemanske RF. Asthma. N Engl J Med 2001; 344: 350-62.
8. Mattes J, Foster PS. Regulation of eosinophil migration and Th2 cell function by IL-5 and eotaxin. Curr Drug Targets Inflamm Allergy 2003; 2: 169-74.
9. Shen HH, Ochkur SI, McGarry MP, et al. A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse. J Immunol 2003; 170: 3296-305.
10. Cho JY, Miller M, Baek KJ, et al. Inhibition of airway remodeling in IL-5 - deficient mice. J Clin Invest 2004; 113: 551-60.
11. Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003; 111: 714-9.
12. Simon D, Braathen LR, Simon HU. Anti-interleukin-5 antibody therapy in eosinophilic diseases. Pathobiology 2005; 72: 287-92.
13. Sutton SA, Assa'ad AH, Rothenberg ME. Anti-IL-5 and hypereosinophilic syndromes. Clin Immunol 2005; 115: 51-60.
14. Popescu FD. Antisense- and RNA interference-based therapeutic strategies in allergy. J Cell Mol Med 2005; 9: 840-53.
15. + T lymphocytes of asthmatic rats. Chinese J Intern Med 2006, 45: 298-301. (in Chinese)
16. Hirano A, Kanehiro A, Ono K, et al. Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. Am J Respir Cell Mol Biol 2006; 35: 366-77.
17. Tan GH, Su JM, Wang CC, et al. A recombinant DNA plasmid encoding the human interleukin-5 breaks immunological tolerance and inhibits airway inflammation in a murine model of asthma. Int Arch Allergy Immunol 2008; 145: 313-23.
18. Hamelmann E, Schwarze J, Takeda K, et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997; 156: 766-75.
19. Webb DC, McKenzie AN, Koskinen AM, Yang M, Mattes J, Foster PS. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol 2000; 165: 108-13.
20. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978; 75: 280-4.
21. Crooke ST. Vitravene--another piece in the mosaic. Antisense Nucleic Acid Drug Dev 1998; 8: vii-viii.
22. Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006; 33: 533-40.
23. Rayburn E, Wang W, Zhang R, Wang H. Antisense approaches in drug discovery and development. Prog Drug Res 2005; 63: 227-74.
24. Dean NM, Bennett CF. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003; 22: 9087-96.
25. Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007; 5: 215-20.
26. Sewell KL, Geary RS, Baker BF, et al. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J. Pharmacol Exp Ther 2002; 303: 1334-43.
27. Humbert M. Pro-eosinophilic cytokines in asthma. Clin Exp Allergy 1996; 26: 123-7.
28. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992; 79: 3101-9.
29. Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 1989; 73: 1504-12.
30. Robinson DS, Ying S, Bentley AM, et al. Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. J Allergy Clin Immunol 1993; 92: 397-403.
31. Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR. Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993; 92: 313-24.
32. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298-304.
33. Tournoy KG, Kips JC, Pauwels RA. The allergen-induced airway hyperresponsiveness in a human-mouse chimera model of asthma is T cell and IL-4 and IL-5 dependent. J Immunol 2001; 166: 6982-91.
34. Leckie MJ, Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000; 356: 2144-8.
35. Hildinger M, Auricchio A. Advances in AAV-mediated gene transfer for the treatment of inherited disorders. Eur J Hum Genet 2004; 12: 263-71.
36. Zhang PX, Fuleihan RL. Transfer of activation-dependent gene expression into T cell lines by recombinant adeno-associated virus. Gene Therapy 1999; 6: 182-9.
37. Hanazono Y, Brown KE, Handa A, et al. In vivo marking of rhesus monkey lymphocytes by adeno-associated viral vectors: direct comparison with retroviral vectors. Blood 1999; 94: 2263-70.
38. Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791-801.
39. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006; 14: 316-27.
40. Warrington KH, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 2006; 119: 571-603.